drugset
drugset / Trial / NCT03395873

Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy

NCT03395873 ↗

Phase 1 Terminated 7 enrolled Milton S. Hershey Medical Center Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to test the safety of combination treatment with Avelumab and Decitabine in newly diagnosed AML patients who are unfit for intensive induction chemotherapy.

Timeline

Start
2018-01-29
Primary completion
2019-05-15
Completion
2019-05-15

Outcome

Outcome not reported

Stopped: “Recent FDA approval of a new drug for the same patient population”

Drugs

EvaluationDrugModalityDoseRoute
Subject Avelumab Monoclonal antibody 10 mg/kg Intravenous
Background Decitabine Small molecule 20 mg/m2 Intravenous

Indications

acute myeloid leukemia